126811-31-2

Usage

Uses

Used in Pharmaceutical Industry:
4,7-DIBROMO-1H-INDOLE is used as a reagent for the synthesis of carbazole carboxamide based inhibitors. These inhibitors are specifically designed for the treatment of lymphatic leukemia, a type of cancer that affects the lymphatic system. The compound plays a crucial role in the development of these inhibitors, contributing to their therapeutic potential and effectiveness in combating the disease.

InChI:InChI=1/C8H5Br2N/c9-6-1-2-7(10)8-5(6)3-4-11-8/h1-4,11H

Upstream product

• 106-37-6 1.4-dibromobenzene 
• 3460-18-2 1,4-dibromo-2-nitrobenzene 
• 1826-67-1 vinyl magnesium bromide 

Downstream Products

• 1312544-35-6 (3-{7-[3-(pyrrolidine-1-carbonyl)-phenyl]-1H-indol-4-yl}-phenyl)-pyrrolidin-1-yl-methanone 
• 1312544-37-8 (3-{7-[3-(piperidine-1-carbonyl)-phenyl]-1H-indol-4-yl}-phenyl)-piperidin-1-yl-methanone 
• 1312544-33-4 4,7-bis-(3-fluoro-phenyl)-1H-indole 
• 1312544-36-7 C₃₀H₃₃N₃O₂ 
• 1326217-54-2 4,7-bis(4-methylbenzyl)-1H-indole 
• 1403612-07-6 4,7-diphenyl-1H-indole 
• 1403612-08-7 4,7-di-p-tolyl-1H-indole 
• 1309980-17-3 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-7-carboxamide 
• 1211596-82-5 4-bromo-1H-indole-7-carboxamide 
• 1258959-58-8 7-bromo-1H-indole-4-carbonitrile 
• 1167055-46-0 4-bromo-1H-indole-7-carbonitrile 
• 292636-21-6 N-(4-bromo-3-chloro-1H-indol-7-yl)-4-nitro-benzenesulfonamide 
• 165668-52-0 N-(4-Bromo-1H-indole-7-yl)-4-nitrobenzenesulfonamide 
• 604788-42-3 4-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole 

Relevant academic research and scientific papers

Aromatic ring liquid crystal compound and liquid crystal composition and application thereof

The invention relates to an aromatic ring liquid crystal compound, a liquid crystal composition and an assembly suitable for a microwave region and a millimeter wave region of a high-frequency technology or an electromagnetic spectrum, and particularly a phase shifter and a microwave array antenna. The liquid crystal composition provided by the invention at least comprises a compound represented by a general formula I. The liquid crystal composition provided by the invention is good in stability, high in response speed and wide in liquid crystal phase temperature range.

Conversion of carbazole carboxamide based reversible inhibitors of Bruton's tyrosine kinase (BTK) into potent, selective irreversible inhibitors in the carbazole, tetrahydrocarbazole, and a new 2,3-dimethylindole series

Incorporation of a suitably-placed electrophilic group transformed a series of reversible BTK inhibitors based on carbazole-1-carboxamide and tetrahydrocarbazole-1-carboxamide into potent, irreversible inhibitors. Removal of one ring from the core of these compounds provided a potent irreversible series of 2,3-dimethylindole-7-carboxamides having excellent potency and improved selectivity, with the additional advantages of reduced lipophilicity and molecular weight.

INDOLE CARBOXAMIDE COMPOUNDS

Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR4 or N; R1, R2, R3, R4, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment o

CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS

Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, formula (I) are useful as kinase modulators, including Btk modulation.

4,7-Diaryl indole-based fluorescent chemosensor for iodide ions

Simple and selective indole based fluorescent sensors for iodide anions are reported. A series of 4,7-diaryl indole derivatives (DAIs) are designed and synthesized using Suzuki coupling. These DAIs shows significant changes in UV-vis and fluorescent intensity only with addition of iodides and not with other anions. The ability of these DAIs to function as selective iodide chemosensor is reported.

Annulated diketopiperazines from dipeptides or schoellkopf reagents via tandem cyclization-intramolecular N-arylation

Figure presented Facile CuI-mediated N-arylation of diketopiperazine using the Fukuyama modification of the Ullmann-Goldberg reaction can be exploited in new approaches to enantiopure polycyclic diketopiperazines from easily assembled dipeptides or functi

1,2,4-OXADIAZOL DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS SPHINGOSINE 1-PHOSPHATE 1 RECEPTOR AGONISTS

1,2,4-Oxadiazol derivatives represented by formula (I) useful as sphingosine 1-phosphate 1 (S1P1) receptor agonists, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders mediated via S1P1 receptor are disclosed.

Integrin expression inhibitors

The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. In the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, —CH═CH— or —(CR4bR5b)mb— (wherein R4b and R5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and mb means an integer of 1 or 2); R1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or —CO—NH—; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.

INTEGRIN EXPRESSION INHIBITORS

The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. In the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, -CH=CH- or - (CR4bR5b)mb- (wherein R4b and R5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and mb means an integer of 1 or 2); R1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or -CO-NH-; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.